1. ESMO 2021

   • Rupert Bartsch

   editorial 07 June 2022 Pages: 95 - 96

2. New targeted therapies/small molecules in oncology and hematology

   • Anna Sophie Berghoff

   editorial 07 June 2022 Pages: 97 - 97

3. COVID-19 crisis and cancer

   • Rupert Bartsch
   • Wolfgang Hilbe

   editorial 07 June 2022 Pages: 98 - 99

4. COVID-19: New disease mechanism is simultaneously a therapeutic target

   • Clemens A. Schmitt

   editorial 07 June 2022 Pages: 100 - 101

5. Renal cell carcinoma—presentation highlights from the ESMO Congress 2021

   • Georg C. Hutterer
   • Martin Pichler

   short review 01 April 2022 Pages: 102 - 106

   

6. Highlights ESMO 2021—lung cancer

   • Markus Rauter

   review 14 April 2022 Pages: 107 - 110

   

7. ESMO 2021—my top three abstracts in breast cancer

   • Christoph Suppan

   short review Open access 06 May 2022 Pages: 111 - 113

8. ESMO 2021—highlights in colorectal cancer

   • Lukas Weiss

   short review Open access 28 April 2022 Pages: 114 - 116

9. Breast Cancer—Essential news of current guidelines

   • Kathrin Strasser-Weippl

   short review 31 March 2022 Pages: 117 - 120

10. Agony of choice—selecting chronic lymphocytic leukemia treatment in 2022

    • Jan-Paul Bohn

    short review Open access 14 April 2022 Pages: 121 - 124

11. Antibody–drug conjugates—the magic bullet?

    • Marie-Bernadette Aretin

    short review Open access 04 February 2022 Pages: 125 - 128

    

12. Current state of clinical development of TROP2-directed antibody–drug conjugates for triple-negative breast cancer

    • Maximilian Marhold

    short review Open access 23 December 2021 Pages: 129 - 132

13. New targeted therapies in kidney cancer

    • Karl Mayrhofer
    • Dora Niedersüß-Beke

    short review 22 December 2021 Pages: 133 - 136

14. Tracking mutation and drug-driven alterations of oncokinase conformations

    • Andreas Feichtner
    • Valentina Kugler
    • Eduard Stefan

    short review Open access 21 January 2022 Pages: 137 - 142

    

15. Systemic capillary leak syndrome following granulocyte colony-stimulating factor therapy in a T-lymphoblastic leukemia/lymphoma patient: a case report

    • Ahmed H. Al Sharie
    • Yazan O. Al Zu’bi
    • Dima Albals

    case report 21 January 2022 Pages: 143 - 148

    

16. Hemophagocytic lymphohistocytosis in a COVID-19 patient in the acute phase: case report

    • Maher Salamoon
    • Mazen Kenj

    case report 15 June 2021 Pages: 149 - 152

    

17. High mortality in patients with active malignancy and severe COVID-19

    • Simon Udovica
    • Nino Müser
    • Ercan Müldür

    original report 06 May 2022 Pages: 153 - 160

    

18. Cardiopulmonary sequelae of COVID-19

    interview 11 April 2022 Pages: 161 - 164

19. Neurotoxicity as a rare side effect of immune checkpoint inhibitors. A case report and review of the literature

    • Simon Udovica
    • Kathrin Strasser-Weippl
    • Dora Niedersüß-Beke

    case report 09 May 2022 Pages: 165 - 168

    

20. Immunotherapy pitfall: sarcoid-like reaction mimicking disease progression in advanced melanoma treated with nivolumab

    • Beatrix Mutschlechner
    • Susanne Dertinger
    • Thomas Winder

    case report 10 May 2022 Pages: 169 - 172